Year archive

Sunshine Lake Pharma Co., Ltd. — 2026 filings

All 36 regulatory filings released by Sunshine Lake Pharma Co., Ltd. (6887) in 2026, sourced directly from the official regulator.

36 Filings

2026 Period

2026 filings (36)

Filing	Released	Lang
INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE IN RESPECT OF THE H SHARE FULL CIRCULATION Regulatory Filings	2026-05-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 Regulatory Filings	2026-05-06	English
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE MARKETING APPROVAL OF INSULIN GLARGINE INJECTION BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) Regulatory Filings	2026-05-04	English
2025 Environmental, Social and Governance Report Regulatory Filings	2026-04-30	English
Annual Report 2025 Regulatory Filings	2026-04-30	English
INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY Capital/Financing Update	2026-04-29	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-28	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-23	English
VOLUNTARY ANNOUNCEMENT THREE INNOVATIVE DRUGS OF THE GROUP SHOWCASED AT THE 2026 AACR ANNUAL MEETING HIGHLIGHTING A DIVERSIFIED PIPELINE IN TUMOR IMMUNOTHERAPY AND PRECISION TARGETED THERAPY Regulatory Filings	2026-04-23	English
Next Day Disclosure Return Regulatory Filings	2026-04-21	English
Next Day Disclosure Return Regulatory Filings	2026-04-20	English
Next Day Disclosure Return Regulatory Filings	2026-04-17	English
VOLUNTARY ANNOUNCEMENT IN RELATION TO MIXED PROTAMINE HUMAN INSULIN INJECTION (30R) - PREFILLED PEN-TYPE OBTAINED MARKETING APPROVAL FROM CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2026-04-16	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-15	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-14	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-10	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-09	English
Next Day Disclosure Return Regulatory Filings	2026-04-08	English
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF DRUG MARKETING AUTHORISATION APPLICATION FOR VONOPRAZAN FUMARATE AND SODIUM CHLORIDE INJECTION Regulatory Filings	2026-04-08	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-02	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-01	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 Regulatory Filings	2026-04-01	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 Earnings Release FY 2025	2026-03-31	English
NOTICE OF BOARD MEETING Report Publication Announcement	2026-03-19	English
POSITIVE PROFIT ALERT Earnings Release FY 2025	2026-03-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 Regulatory Filings	2026-03-03	English
VOLUNTARY ANNOUNCEMENT THE ACCEPTANCE BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR HEC-648 INJECTION, A MONOCLONAL ANTIBODY TARGETING THE G PROTEIN OF Regulatory Filings	2026-02-24	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 Transaction in Own Shares	2026-02-03	English
VOLUNTARY ANNOUNCEMENT ENTERING INTO A STRATEGIC COOPERATION FRAMEWORK AGREEMENT Regulatory Filings	2026-01-26	English
VOLUNTARY ANNOUNCEMENT CORE PRODUCT OLORIGLIFLOZIN CAPSULES OBTAINED MARKETING APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2026-01-16	English
VOLUNTARY ANNOUNCEMENT LAUNCH OF A WORLD-LEADING AI-POWERED R&D PLATFORM FOR PROTAC MECHANISM Regulatory Filings	2026-01-14	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-06	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-05	English
VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT ON PHASE I CLINICAL TRIAL OF HECN30227 (siRNA THERAPEUTIC TARGETING HEPATITIS B VIRUS) AND PROGRESS IN THE DEVELOPMENT OF SMALL NUCLEIC ACID PLATFORM Regulatory Filings	2026-01-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 Transaction in Own Shares	2026-01-05	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-02	English